DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/fv6qlb/hairy_cell)
has announced the addition of the Hairy
Cell Leukemia – Pipeline Review, H1 2015 report to their
offering.

This report provides comprehensive information on the therapeutic
development for Hairy Cell Leukemia, complete with comparative analysis
at various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Hairy
Cell Leukemia and special features on late-stage and discontinued
projects.

The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens Ramp;D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.

Scope

– The report provides a snapshot of the global therapeutic landscape of
Hairy Cell Leukemia

– The report reviews key pipeline products under drug profile section
which includes, product description, MoA and Ramp;D brief, licensing and
collaboration details amp; other developmental activities

– The report reviews key players involved in the therapeutics
development for Hairy Cell Leukemia and enlists all their major and
minor projects

– The report summarizes all the dormant and discontinued pipeline
projects

– A review of the Hairy Cell Leukemia products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources

– Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages

– A detailed assessment of monotherapy and combination therapy pipeline
projects

– Coverage of the Hairy Cell Leukemia pipeline on the basis of target,
MoA, route of administration and molecule type

– Latest news and deals relating related to pipeline products

Companies Mentioned

– Astellas Pharma Inc.

– AstraZeneca PLC

– Biogenomics Limited

– F. Hoffmann-La Roche Ltd.

– GlaxoSmithKline plc

– Inbiopro Solutions Pvt. Ltd.

– Incyte Corporation

– MedImmune, LLC

– Plexxikon Inc.

For more information visit http://www.researchandmarkets.com/research/fv6qlb/hairy_cell

article source